Abstract: Disclosed in the present invention is micellar polypeptide vaccine having pegylated phospholipid as carrier. The vaccine can prevent or treat tumors or can be used as combination formulation with anti-cancer activity formulation. The micellar polypeptide vaccine is formed of self-assembling pegylated phospholipid (PEG-PE) and antigenic polypeptides, the pegylated phospholipid being compound formed of polyethylene glycol (hydrophilic blocks) covalently bonded to nitrogenous bases on phospholipid molecule (hydrophobic blocks). The particle diameter of the micellar vaccine is 10-100 nm, and the antigenic polypeptides carried therein are polypeptides of 5-100 amino acids. The micellar polypeptide vaccine may also contain immunoadjuvant.
Type:
Grant
Filed:
October 19, 2015
Date of Patent:
January 7, 2020
Assignee:
SHANGHAI TIANHUI CHEMICAL PHARMACEUTICAL CO. LTD
Abstract: This document provides methods and materials related to assessing prostate cancer in mammals. For example, this document provides nucleic acids and polypeptides that can be analyzed to determine whether a male mammal having prostate cancer is susceptible to a good or poor outcome.
Type:
Grant
Filed:
December 14, 2016
Date of Patent:
December 3, 2019
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
George Vasmatzis, John C. Cheville, Farhad Kosari, Cemile D. Savci-Heijink, Eric W. Klee, Jan Marie A. Willard, Lori S. Tillmans
Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.
Type:
Grant
Filed:
January 14, 2014
Date of Patent:
November 26, 2019
Assignee:
Xencor, Inc.
Inventors:
Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
Abstract: Methods for targeted breast cancer therapy in a subject based upon evaluating the stromal subtypes and CD146 composition in the adjacent tissue. ER+ breast cancers contain two CAF subtypes defined by CD146 expression. CD146neg CAFs suppress ER expression in ER+ breast cancer cells, decrease tumor cell sensitivity to estrogen, switch ER proliferation dependency toward EGFR dependency and decrease tumor cell sensitivity to antiendocrine therapy. Conversely, the presence of CD146pos CAFs enhances ER expression in ER+ breast cancer cells and sustains ER-dependent proliferation and sensitivity to tamoxifen. Co-cultures of CD146pos CAFs with tamoxifen-resistant breast cancer cells restores sensitivity to tamoxifen. Gene expression profiles of patient breast tumors with predominantly CD146neg CAFs correlate with inferior clinical response to tamoxifen and worse patient outcomes. CAF composition contributes to treatment response and patient outcomes in ER+ breast cancer, and provide a target for drug development.
Type:
Grant
Filed:
June 8, 2017
Date of Patent:
November 26, 2019
Assignee:
The Regents of the University of Colorado, a body corporate
Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A? is a Stretcher unit, and p is from about 3 to about 5.
Abstract: The present invention relates to a method to modulate the level of activation of an engineered immune cell (such as a Chimeric Antigen Receptor T-cell) for immunotherapy. The present invention also relates to cells obtained by the present method, preferably comprising said modulable/tunable chimeric antigen receptors for use in therapeutic or prophylactic treatment.
Type:
Grant
Filed:
October 7, 2015
Date of Patent:
November 12, 2019
Assignee:
CELLECTIS
Inventors:
Philippe Duchateau, Alexandre Juillerat, Laurent Poirot
Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.
Type:
Grant
Filed:
June 26, 2017
Date of Patent:
November 12, 2019
Assignee:
Xencor, Inc.
Inventors:
John Desjarlais, Gregory Moore, Rumana Rashid, Matthew Bernett
Abstract: The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.
Type:
Grant
Filed:
September 4, 2018
Date of Patent:
November 5, 2019
Assignee:
EUREKA THERAPEUTICS, INC.
Inventors:
Jingwei Lu, Zhiyuan Yang, Cheng Liu, Hong Liu, Yiyang Xu, Su Yan, Vivien Wai-Fan Chan, Lucas Horan
Abstract: It has been discovered that the human GT198 gene (gene symbol PSMC3IP) at chromosome 17q21 acts as a tumor suppressor. The mutation of the GT198 gene causes the increased dominant negative splice variant activity and leads to the loss of wild type GT198 function, and in turn, induces breast and ovarian cancers. One embodiment provides compositions and methods for treating or alleviating one or more symptoms associated with cancer due to the GT198 gene mutations. Another embodiment provides methods and compositions for detecting cancer due to the mutation of the GT198 gene. Still another embodiment provides methods for identifying compounds, antibodies and natural product molecules that are useful for treating cancer due to the mutations of the GT198 gene. Preferably the disclosed compositions antagonize or interfere with the biological activity of splice variants of GT198.
Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
Type:
Grant
Filed:
February 8, 2018
Date of Patent:
October 8, 2019
Assignees:
SILLAJEN, INC, SILLAJEN BIOTHERAPEUTICS, INC.
Inventors:
David Kirn, John Bell, Caroline Breitbach, Anne Moon, Tae-Ho Hwang, Yu Kyoung Lee, Mi-kyung Kim
Abstract: The instant invention provides for a new method of treating bone metastasis diseases in subjects, wherein said method preferably depends on whether the subject shows certain specific proteins levels in one or more body fluids prior to or during treatment, wherein said treatment comprises the administration of at least one pan ?v integrin inhibitor to a subject, a medicament for use in said new methods, and a method of predicting the outcome of a treatment with at least one pan ?v integrin inhibitor based on said specific protein levels in one or more body fluids of the subject.
Abstract: The present invention relates to compositions and detection systems of antibodies or fragments thereof, wherein at least two antibodies or fragments thereof binds specifically to squamous cell carcinoma (SCC) and/or adenocarcinoma (ADC). Methods for using the antibodies in diagnosis, prognosis, and assessing efficacy of treatment is further included as well as kits including such compositions and detection systems.
Abstract: The present disclosure is generally directed to profiling peptides, compositions, and kits, as well as methods of use thereof. The profiling peptides comprise an Mcl-1 binding domain, and optionally a cellular uptake moiety. The methods of using such profiling peptides include predicting sensitivity of a cancer, selecting a treatment, treating a cancer, producing a sensitivity profile, and the like.
Type:
Grant
Filed:
February 19, 2019
Date of Patent:
September 24, 2019
Assignee:
TOLERO PHARMACEUTICALS, INC.
Inventors:
David J. Bearss, Adam Siddiqui-Jain, Clifford J. Whatcott, Peter W. Peterson, Steven L. Warner, Lars Mouritsen
Abstract: Provided herein are new compositions and methods to target pharmaceutical agents to pathological areas by utilizing bifunctional fusion polymers or nanoparticles. These fusion polymers and nanoparticles contain two or more domains: (i) sequences that bind to exposed collagenous (XC-) proteins present in pathological areas, including cancerous lesions and (ii) domains that bind to pharmaceutical agents. The drug-binding functionality of these fusion polymers and nanoparticles is based on high-affinity, non-covalent interactions.
Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. The present invention also relates to a humanized antibody that specifically binds human TrkB and methods for producing and using the antibody to, inter alia, treat a hearing loss disorder.
Type:
Grant
Filed:
May 13, 2015
Date of Patent:
August 27, 2019
Assignee:
PFIZER INC.
Inventors:
Eric M. Bennett, Nathan Higginson-Scott, Lioudmila Tchistiakova, Kimberly A. Marquette, Janet E. Paulsen, Ruth E. Gimeno
Abstract: Natural-KilleifT-Cell Lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy. The invention relates to a method for predicting Natural Killer T-cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject comprising testing for JAK mutations. The invention also relates to a method of screening for candidate agents capable of treating NKTCL using a cell line comprising at least one JAK mutation. The invention includes an NKTCL animal model comprising at least one JAK mutation. The invention also includes JAK inhibitors for treating NKTCL.
Type:
Grant
Filed:
June 6, 2016
Date of Patent:
August 13, 2019
Assignee:
SINGAPORE HEALTH SERVICES PTE LTD
Inventors:
Bin Tean Teh, Soon Thye Lim, Choon Kiat Ong
Abstract: The present disclosure relates to an antibody binding to Neuropilin 1 (NRP1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for preparing the antibody or the antigen-binding fragment thereof, an antibody-drug conjugate comprising the antibody or the antigen-binding fragment thereof, and a composition thereof for preventing or treating a cancer.
Type:
Grant
Filed:
December 3, 2015
Date of Patent:
July 30, 2019
Assignee:
SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
Inventors:
Do-Hyun Nam, Yeup Yoon, Jae Hyun Lee, Jin Ku Lee